FDA Labeling Draft Encourages Graphics for Pharmacology

The clinical pharmacology section of a drug label should generally contain positive and pertinent negative findings about the product and should avoid repeating information contained elsewhere on the label as much as possible, the FDA says in a draft guidance. The draft encourages the inclusion of graphs and tables, including variability information. Comments are due June 1.
Washington Drug Letter